Could a single infusion of 'Peacekeeper' cells let kidney transplant patients ditch most of their meds?
Disease control
Recruiting now
This phase 2 trial tests whether a single infusion of a patient's own regulatory T cells (TRK-001) can prevent the immune system from attacking a new kidney. 34 living-donor kidney transplant recipients will either receive standard anti-rejection drugs alone or those drugs plus t…
Phase: PHASE2 • Sponsor: Singulera Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC